Article published In: Information Design Journal
Vol. 25:3 (2019) ► pp.308–314
Information about medicines in Europe
Considering possible principles?
Published online: 22 October 2020
https://doi.org/10.1075/idj.25.3.08van
https://doi.org/10.1075/idj.25.3.08van
Abstract
The development of information about medicines for patients in the last thirty years provides a fascinating
information design case study. Throughout this period three main principles have remained stable: an absolute focus on patients,
performance based design, and a thorough design process. These principles are likely to remain valid for future developments.
Keywords: information about medicines, process, performance, patients
Article outline
- A brief historical overview: We’ve come a long way
- Can this current situation be seen as successful?
- Can we provide these ‘Principles of good information design’?
- Question 1: Who reads these texts: Users, readers, patients?
- Question 2: What needs to be achieved and how can that be established?
- Question 3: What are information design processes?
- Two assumptions are in conflict with these principles
- The next steps
References
References (21)
Black, A., Luna, P., Lund, O., & Walker, S. (2017). Information design: Research and practice. London: Routledge.
Collins, P. H. (1990). Black feminist thought: Knowledge, consciousness, and the politics of empowerment. London: Routledge.
Constanza-Chock, S. (2020). Design justice: Community-led practices to build the worlds we need. Cambridge, MA: MIT press.
European Commission. (2017). Report from the commission to the European Parliament and the Council. com(2017) 135 final. [URL]
EMA. (2017). EMA action plan related to the European Commission’s recommendations on product information. (EMA/680018/2017). [URL]
. (2020). QRD-template version 10.1 (dated 28/06/2019). [URL]
Fuchs, J. (2010). The way forward in package insert user tests from a CRO’s perspective. Drug Information Journal, 44(2), 19–129.
Modell, W. (1967). How to stuff a stuffer and cook a wolf. Pharmacology and Therapeutics, 8(6), 775–781.
Morris, L. A. (1989). The FDAs approach to patient package inserts: The four phases of PPIs. In: M. Bogaert, B. Vander Stacee, J-M. Kaufman, & R. Lefebvre (Eds.), Patient package inserts as a source of drug information (pp. 59–66). Amsterdam: Excerpt Medica.
Gibbs, S. (1990). Informing patients about medicines: An evaluation of prescription information leaflets in general practice (PhD thesis), Faculty of Medicine, University of Southampton.
PIL-S study. (2014). Study on the package leaflets and the summaries of product characteristics of medicinal products for human use. [URL]
PIL-BOX study. (2014). Feasibility and value of a possible “key information section” in patient information leaflets and summaries of product characteristics of medicinal products for human use. [URL]
PubMed. (2020). [URL]
Rupf, R. (1991). Evaluation of patient-oriented drug information: Package leaflets as viewed by the patient and their impact on outpatient’s behaviour during treatment. (PhD thesis). University of Basel: Faculty of Philosophy and Natural Sciences.
Sless, D. (1992). What is information design? In: R. Penman & D. Sless (Eds.), Designing information for people (pp. 1–16). Canberra: Communication Research press.
Sless, D. & Shrensky, R. (2006). Writing about medicines for people. Australian Self-Medication Industry. [A first edition was published in 1994 by David Sless and Rob Wiseman for the Department of Health and Family Services.] [URL]
Vander Stichele, R. (2004). Impact of written drug information in patient package inserts (PhD Thesis). Ghent University, Faculty of Medicine and Health Science.
Van der Waarde, K. (1993). An investigation into the suitability of the graphic presentation of patient package inserts (PhD thesis). University of Reading, Department of Typography & Graphic Communication.
(2008). Measuring the quality of information in medical package leaflets: Harmful or helpful? Information Design Journal, 16(3), 16–228.